...
首页> 外文期刊>Molecular pharmaceutics >Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: A targeted approach for the treatment of psoriasis
【24h】

Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: A targeted approach for the treatment of psoriasis

机译:他克莫司经皮肤递送的聚合物胶束纳米载体:银屑病的靶向治疗方法

获取原文
获取原文并翻译 | 示例
           

摘要

Tacrolimus (TAC) suffers from poor cutaneous bioavailability when administered topically using conventional vehicles with the consequence that although it is indicated for the treatment of atopic dermatitis, it has poor efficacy against psoriasis. The aim of this work was to formulate TAC loaded polymeric micelles using the biodegradable and biocompatible methoxy-poly(ethylene glycol)-dihexyl substituted polylactide (MPEG-dihexPLA) diblock copolymer and to investigate their potential for targeted delivery of TAC into the epidermis and upper dermis. Micelle formulations were characterized with respect to drug content, stability, and size. An optimal 0.1% micelle formulation was developed and shown to be stable over a period of 7 months at 4°C; micelle diameters ranged from 10 to 50 nm. Delivery experiments using human skin and involving quantification by UHPLC-MS/MS demonstrated that this formulation resulted in significantly greater TAC deposition in skin than that with Protopic (0.1% w/w; TAC ointment), (1.50 ± 0.59 and 0.47 ± 0.20 μg/cm2, respectively). The cutaneous biodistribution profile of TAC in the upper 400 μm of tissue (at a resolution of 20 μm) demonstrated that the increase in cutaneous drug levels was due to improved TAC deposition in the stratum corneum, viable epidermis, and upper dermis. Given that there was no increase in the amount of TAC in deeper skin layers or any transdermal permeation, the results suggested that it would be possible to increase TAC levels selectively in the target tissue without increasing systemic absorption and the risk of side effects in vivo. Micelle distribution and molecular penetration pathways were subsequently visualized with confocal laser scanning microscopy (CLSM) using a fluorescently labeled copolymer and fluorescent dyes. The CLSM study indicated that the copolymer was unable to cross the stratum corneum and that release of the micelle "payload" was dependent on the molecular properties of the "cargo" as evidenced by the different behaviors of DiO and fluorescein. A preferential deposition of micelles into the hair follicle was also confirmed by CLSM. Overall, the results indicate that MPEG-dihexPLA micelles are highly efficient nanocarriers for the selective cutaneous delivery of tacrolimus, superior to the marketed formulation (Protopic). Furthermore, they may also have significant potential for targeted delivery to the hair follicle.
机译:他克莫司(TAC)当使用常规媒介物局部给药时,皮肤生物利用度较差,其结果是,尽管已表明他克莫司可用于治疗特应性皮炎,但其抗牛皮癣的功效较差。这项工作的目的是使用可生物降解和生物相容性的甲氧基-聚(乙二醇)-二己基取代的聚丙交酯(MPEG-dihexPLA)二嵌段共聚物配制载有TAC的聚合物胶束,并研究其将TAC靶向递送至表皮和上层的潜力。真皮关于胶束制剂的药物含量,稳定性和大小进行了表征。开发出了最佳的0.1%胶束配方,并在4°C下可稳定7个月;胶束直径范围为10至50 nm。使用人类皮肤并通过UHPLC-MS / MS进行定量的递送实验表明,与Protopic(0.1%w / w; TAC软膏)(1.50±0.59和0.47±0.20μg)相比,该制剂导致皮肤中的TAC沉积明显增加/ cm2)。 TAC在上部400μm组织中的皮肤生物分布特征(分辨率为20μm)表明,皮肤药物水平的增加归因于TAC在角质层,活表皮和上层真皮中沉积的改善。鉴于在较深的皮肤层或任何透皮渗透中TAC的含量没有增加,结果表明可以在不增加全身吸收和体内副作用风险的情况下,有选择地提高靶组织中TAC的水平。随后,使用荧光标记的共聚物和荧光染料通过共聚焦激光扫描显微镜(CLSM)观察胶束的分布和分子渗透途径。 CLSM研究表明,该共聚物无法穿过角质层,胶束“有效载荷”的释放取决于“货物”的分子特性,这由DiO和荧光素的不同行为所证明。 CLSM还证实了胶束优先沉积在毛囊中。总的来说,结果表明,MPEG-dihexPLA胶束是用于他克莫司选择性皮肤递送的高效纳米载体,优于市售制剂(Protopic)。此外,它们还可能具有靶向递送至毛囊的巨大潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号